2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2386

Integrating Wearable Physical Activity Monitoring Tools into Rehabilitation Practice for Patients with Arthritis: The Healthcare Professional Perspective
Abstract Number: 3129

Integrative Analysis of the Colonic Microbiota in Systemic Sclerosis
Abstract Number: 2106

Intensification to Triple Therapy Non-Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States from 2009 to 2014
Abstract Number: 2913

Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation
Abstract Number: 1873

Inter and Intrarater Reliability of the Modified Rodnan Skin Score in Early Diffuse Systemic Sclerosis
Abstract Number: 407

Inter-Observer Variability of the Histological Classification of Lupus Glomerulonephritis in Children
Abstract Number: 3147

Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease
Abstract Number: 1962

Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis
Abstract Number: 1321

Inter-Reader Agreement of a Novel Method of Radiographic Scoring of Rheumatoid Arthritis
Abstract Number: 2467

Interaction Between Senescent T Cells and Fibrocyte-like Cells through CD31, TNFα, and IL-17 Create a Tissue Destructive Environment in the Synovium in Juvenile Idiopathic Arthritis
Abstract Number: 3113

Interest of Assessing Anti-Drug Antibodies for the Choice Between a Second Anti-TNF and a Non-TNF-Targeted Biologic in Patients with Inadequate Response to a First Anti-TNF : Results from the Randomized Controlled Trial « Rotation or Change »
Abstract Number: 805

Interferon Activity in Early and Established SLE: Interferon Score Is Lower in Early Disease and Not Seen without Antibodies to Extractable Nuclear Antigens
Abstract Number: 3076

Interferon Gamma (IFNg) Is the Driving Mediator of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in TLR9-Mediated Pathogenesis in Mice and Is Correlated to Disease Parameters in Children
Abstract Number: 3131

Interferon Regulatory Factor 7 (IRF7): The Possible Link Between Inflammation and Fibrosis in SSc Pathogenesis
Abstract Number: 803

Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].